Promising combo tackles Hard-to-Treat breast cancer
NCT ID NCT07647016
First seen Jun 18, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two drugs—deruxtecan (a targeted chemotherapy) and ivonescimab (an immunotherapy)—in people with hormone receptor-positive, HER2-negative advanced breast cancer. The study aims to see how well the combination shrinks tumors and how safe it is. About 53 participants will be enrolled at Fudan University in Shanghai.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab Deruxtecan (a targeted chemotherapy) and Ivonescimab (an immunotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with hormone receptor-positive, HER2-negative advanced breast cancer, including those with brain metastases.
What could go wrong
This is a small, early-phase study with only 53 participants and no comparison group, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.